Technology Innovation Institute’s Secure Systems Research Centre Partners with Purdue University on Game-Changing UAV Security Project
10.3.2021 13:29:00 EET | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), today announced that its Secure Systems Research Centre (SSRC) has partnered with Purdue University, a world-renowned US-based public research university. The two entities are collaborating on a three-year sophisticated cybersecurity project to ensure Unmanned Aerial Vehicles (UAVs) can be used safely and efficiently in urban operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005409/en/
Dr Shreekant Thakkar, Chief Researcher, Secure Systems Research Centre (SSRC), Technology Innovation Institute (TII) - (Photo: AETOSWire)
Secure Systems Research Centre is one of initial seven dedicated research centres at TII. The research collaboration with Purdue University, titled ‘Cybersecurity for UAS Operations in Urban Environment’, includes the study of security and resilience in cyber-physical and autonomous systems. The project examines safety challenges that Unmanned Aerial Systems (UASs) experience in operating environments. These systems and vehicles are vulnerable to sophisticated cyberattacks in terms of communication, navigation, surveillance, and command and control. The outcome of this research will help other research at Secure Systems Research Centre in the future.
Dr Shreekant (Ticky) Thakkar, Chief Researcher at Secure Systems Research Centre leading the Secure Autonomous Computing work, said: “Our world is becoming increasingly complex. This is evidenced by the rising number of cyberattacks and surveillance breaches that occur daily. We must regain control over critical digital systems. We are optimistic that the research outcomes at TII’s Secure Systems Research Centre will allow us to gain the upper hand in the fight against these malicious attacks.”
He added: “We are delighted to have the Purdue Team led by Prof. Inseok Hwang of School of Aeronautics and Astronautics partner on making cyber-physical and autonomous systems secure and resilient to malware using their state of the art autonomous drone testing facility. This will enable commercial autonomous drones and robots growth in the UAE and worldwide, opening new opportunities to enterprises and making their use safer for all people.”
A multidisciplinary group of researchers from Purdue University will join forces with TII’s Secure Systems Research Centre team.
The research project comprises four phases of development. First, it will carry out a modelling and analysis of UAS security. Second, it will develop algorithms and methodologies for high-assurance autonomy. Third, it will construct an experimental environment and work to simulate safe and secure urban UAS operations. Finally, it will test and validate mitigation strategies in a scaled, mixed-reality testbed.
This three-year project is led by Prof. Inseok Hwang as the principal investigator. Prof. Hwang is assisted on this project by two co-researchers from Purdue University – Prof. James Goppert, a visiting assistant professor at the School of Aeronautics and Astronautics and managing director of the UAS Research and Test Facility; and Prof. Dongyan Xu, the Samuel D. Conte Professor of Computer Science and Director of CERIAS (Center for Education and Research in Information Assurance and Security), Purdue’s cybersecurity research and education center.
Prof. Hwang will assess potential cyberattacks on the systems, Prof. Xu will conduct resource-efficient encryption, multi-UAS communications, and other research from the cyber perspective while Prof. Goppert will test the drones in a special mixed reality environment he will design and build.
Prof. Hwang said: “This landmark project comes at a time of growing reliance on UASs across various sectors – from security to medicine and logistics, and everything in between. We are confident that our partnership will translate into global wins for the international community and lead to many more research milestones in the years to come.”
For more information, please visit www.tii.ae and https://securesystems.tii.ae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005409/en/
Contact information
Technology Innovation Institute
Haitham Haddadin
Haitham.Haddadin@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 16:00:00 EEST | Press release
Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is strengthening its position through the acquisition of a VCSEL company for short-range communications five years ago and the completion of 100G (25G×4) class technology. Furthermore, Seoul Viosys is ex
vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 15:51:00 EEST | Press release
vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports enamel repair by facilitating the formation of crystalline mineral structure throughout the affected area, giving dental professionals an easy-to-use, restorative opti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
